What is the appropriate evaluation for prurigo nodularis in a post‑menopausal woman?

Evaluation of Prurigo Nodularis in a Post-Menopausal Female

In a post-menopausal woman with prurigo nodularis, begin with a complete blood count and ferritin levels, liver and kidney function tests, and consider skin biopsy if diagnosis is uncertain or cutaneous lymphoma is suspected, while systematically screening for common comorbidities including diabetes, thyroid disease, and malignancy based on clinical presentation. 1

Initial Clinical Assessment

The diagnostic workup should focus on:

• Duration of symptoms: Pruritus lasting at least 6 weeks with firm, nodular lesions and evidence of repeated scratching 2
• Distribution pattern: Document location and extent of nodular lesions
• Pruritus intensity: Use numerical rating scale (0-10) to quantify severity 2, 3
• Sleep disruption: Assess impact on quality of life and mental health
• Medication history: Review all current medications as potential triggers 1
• Travel history: Consider parasitic infections if relevant 1

Essential Laboratory Investigations

First-Line Tests (All Patients)

Complete blood count and ferritin levels are mandatory in all patients with chronic prurigo 1. This screens for:

• Iron deficiency anemia (common cause of generalized pruritus)
• Polycythemia vera (check if hemoglobin/hematocrit elevated)
• Eosinophilia (suggests atopic or parasitic etiology)

Comprehensive metabolic panel including:

• Urea and electrolytes (screen for chronic kidney disease) 1
• Liver function tests (evaluate for hepatic causes) 1
• Glucose (screen for diabetes, highly prevalent in PN) 4

Thyroid function tests should be obtained given the high prevalence of thyroid disease in post-menopausal women with PN 4, despite guidelines stating routine endocrine testing is unnecessary unless clinical features suggest endocrinopathy 1. This represents a practical deviation from the guideline given the specific population.

Conditional Second-Line Tests

If hematologic abnormalities present:

• Blood film, lactate dehydrogenase, ESR 1
• JAK2 V617F mutation if polycythemia vera suspected (raised hemoglobin/hematocrit) 1
• Referral to hematology if lymphoma suspected 1

If systemic symptoms present:

• HIV and hepatitis B/C serology 1
• Consider screening for strongyloidiasis, schistosomiasis if travel history positive 1

Additional considerations:

• Vitamin D level (supplementation may help some patients) 1
• Serum IgE and TARC levels if atopic background suspected 5

Skin Biopsy Indications

Consider skin biopsy in the following scenarios:

1. Diagnostic uncertainty: When clinical presentation is atypical 2
2. Persistent unexplained pruritus: To rule out cutaneous lymphoma 1
3. Elderly patients: Pruritus can rarely be the presenting feature of bullous pemphigoid in this population; request direct immunofluorescence 1
4. Suspected neuropathic pruritus: To confirm small fiber neuropathy 1

The biopsy should be taken from an established nodule on the trunk if cutaneous lymphoma is suspected 1.

Comorbidity Screening

Post-menopausal women with PN have high rates of associated conditions 4:

• Metabolic: Diabetes, obesity, thyroid disease
• Renal: Chronic kidney disease
• Hepatic: Chronic liver disease
• Cardiovascular: Hypertension
• Psychiatric: Anxiety, depression (use validated scales like HADS) 6
• Malignancy: Perform thorough history and physical examination, but full malignancy workup is NOT routinely recommended unless systemic symptoms present 1

Important Caveats

Do NOT perform:

• Routine extensive malignancy screening without specific clinical indicators 1
• Routine endocrine panels beyond thyroid function in post-menopausal women (practical exception to guideline) 1

Common pitfalls to avoid:

• Missing iron deficiency despite normal hemoglobin (check ferritin) 1
• Overlooking medication-induced pruritus (review all drugs including over-the-counter) 1
• Failing to assess disease burden and quality of life impact 2, 3
• Not recognizing PN as a distinct primary diagnosis independent of triggers 4

Disease Severity Assessment

Document baseline severity using:

• Investigator's Global Assessment for PN Stage (IGA PN-S) 5
• Worst Itching Intensity Numerical Rating Scale (WI-NRS) 5
• Dermatology Life Quality Index (DLQI) 6
• Number and rate of nodules with erosion/ulceration ("breaking-number" and "breaking-rate") 5

This structured approach ensures comprehensive evaluation while avoiding unnecessary testing, allowing for early diagnosis and appropriate management initiation in this high-burden disease 4.